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Although advances in surgical techniques and bone
grafting have significantly improved the functional and
cosmetic restoration of craniofacial structures lost
because of trauma or disease, there are still significant
limitations in our ability to regenerate these tissues. The
regeneration of oral and craniofacial tissues presents a
formidable challenge that requires synthesis of basic
science, clinical science, and engineering technology.
Tissue engineering is an interdisciplinary field of study
that addresses this challenge by applying the principles of
engineering to biology and medicine toward the devel-
opment of biological substitutes that restore, maintain,
and improve normal function. This review will explore
the impact of biomaterials design, stem cell biology and
gene therapy on craniofacial tissue engineering.
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Introduction
The craniofacial unit is a complex array of bone,
cartilage, soft tissue, nerves and vasculature; giving rise
to the most esthetically important component of the
body. Damage to these structures, even when minimal,
usually leads to noticeable deformity. When changes are
extensive, difficult reconstructive challenges result. In
addition, in the case of tumor treatment, the craniofacial
unit is frequently subjected to radiation and a variety of
chemotherapeutic strategies, creating a compromised
wound bed for reconstructive surgery.
The bones of the craniofacial skeleton provide the
foundation upon which other units are built and while
soft tissue compensation is possible, adequate bony
support is key to the return of both esthetics and
function. For many years, bone grafts (autogenous,
allogenic, and xenogenic) have been the mainstay for
replacement. Current state of the art reconstruction of
large bony maxillofacial defects involves free tissue
transfer with microvascular reanastomosis of vascular-
ized flaps from distant sites including fibula, iliac crest,
scapula, and radius (Disa and Cordeiro, 2000; Emerick
and Teknos, 2007). While these procedures have proven
to be reliable and effective, they require extended
hospitalization, and a secondary donor site with asso-
ciated morbidity and complications. Furthermore, these
techniques struggle to fully replicate normal form and
function. As an alternative to the classic surgical
approaches, developments in tissue engineering, gene
therapy, and stem cell biology strive to utilize cells,
biomaterial scaffolds and cell signaling factors to
regenerate large skeletal defects with precise replication
of normal body contours. A tissue engineering approach
offers several potential benefits, including the lack of
donor site morbidity, decrease in technical sensitivity of
the repair, and most importantly, the ability to closely
mimic the in vivo microenvironment in an attempt to
recapitulate normal craniofacial development.
The optimal bone construct for repair would exactly
replicate the lost structure, be fabricated with techniques
generalizable to laboratories across the world, and
would ultimately be replaced through the body’s normal
physiological processes of homeostasis over time. Fur-
thermore, it would be reliable not only in standard tissue
conditions but also in defects with compromised tissue
beds following infection, radiation, chemotherapy and
the scar of extensive trauma. Although no current
technology meets all of these criteria, progress has been
made in the preclinical arena that gives confidence to
achieving this goal. The purpose of this review is to
provide an overview and update on the current state of
the art in bone reconstruction using new and evolving
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technologies. Discussion will be focused on the broad
categories of tissue engineering, gene therapy, and stem
cell biology with attention to concepts and the current
state of art based on ongoing research. While human
clinical applications are limited to date, great promise
exists as technology and our understanding of these
principles increases over time.
Tissue engineering
Tissue engineering is an interdisciplinary field of study
that applies the principles of engineering to biology and
medicine toward the development of biological substi-
tutes that restore, maintain, and improve normal func-
tion (Langer and Vacanti, 1993; Scheller et al, 2009).
Cells, designed biomimetic materials, and biochemical
signals compose the tissue engineering triad, and the
significant interdependence of all three elements is often
used in concert to produce constructs suitable for
replacement of damaged or diseased tissue. The multi-
disciplinary nature of craniofacial tissue engineering
strategies stems from formidable surgical challenges
faced in the clinical setting, where the need to regenerate
tissue that restores function to oral and craniofacial
structures has long been of great importance (Hollinger
and Winn, 1999; Alsberg et al, 2001; Steiner et al, 2002).
Specifically, craniofacial bony structures such as the
alveolar ridge (Hibi et al, 2006), the maxillary sinus floor
(Shayesteh et al, 2008), and the hard palate (Carstens
et al, 2005) have been reported to be successfully
regenerated using tissue engineering strategies in clinical
studies. Additionally, calvarial bone (Tu et al, 2007) and
the mandibular condyle of the temporomandibular joint
(TMJ) (Alhadlaq and Mao, 2005; Lee et al, 2009) have
been reconstructed successfully in preclinical animal
models. However, given the developmental differences
between the appendicular skeleton (medosdermal origin
– undergoes endochondral ossification) and the cranial
skeleton (neural crest and paraxial mesodermal origin –
undergoes both endochondral and intramembranous
ossification), significant advances in understanding the
complex developmental patterns of the craniofacial unit
must take place to reach the goal of using optimally
designed biomaterials for human clinical applications
(Jiang et al, 2002). Therefore, the engineering design
principles and techniques needed to achieve the goal of
controlling and regenerating components of an intricate
biological tissue system such as the oral and craniofacial
complex are diverse. The focus of this review will be to
describe successful models currently applying these
principles in the preclinical and clinical setting, although
it is important to note that the preclinical findings may
not always translate to the human experience.
In the bone tissue engineering paradigm, the purpose
of the scaffold is to provide an osteoinductive extracel-
lular matrix (ECM) analog to support initial cell
adhesion, growth and development of new bone. Within
the craniofacial tissue engineering field, the major
classes of materials used are natural polymers, synthetic
polymers, ceramics, composite materials, and electro-
spun nanofibers. In addition to selection of the
appropriate material, the scaffold should possess design
characteristics that elicit a biological response from the
microenvironment. Through optimizing design para-
meters and fabrication techniques, the ideal scaffold
candidate is required to achieve the following: (i) to
deliver progenitor cells or facilitate host cell recruitment
via osteoconductive and osteoinductive material proper-
ties; (ii) to deliver important signaling molecules in a
temporally and spatially controlled manner via growth
factor incorporation and surface modification; (iii) to
promote vascularization and tissue in-growth via
changes in microporosity; (iv) to properly fit the shape
of the anatomical defect via image and Computer-Aided
Design (CAD) based scaffold design methods; (v) to
provide initial plasticity while maintaining load-bearing
stability via selection of the appropriate fabrication
technique; and (vi) to degrade into biocompatible by-
products at a rate that matches new tissue formation via
selection of the optimal material composition (Giesen
et al, 2004; Meinel et al, 2004; Hollister, 2005; Mao
et al, 2006; Gersbach et al, 2007; Hutmacher and Cool,
2007; Hutmacher et al, 2007; Wang et al, 2007; Jones
et al, 2009). To address the requirements of scaffolds
specifically for craniofacial bone repair, one must
consider the delicate balance of imparting sufficient
porosity, permeability, and pore architecture to facili-
tate vascular invasion, mass transport, and cell survival
in the scaffold interior, while maintaining the ability to
withstand load bearing conditions that craniofacial bone
sustains as a result of oral functions such as mastication,
deglutition, and speech (Hollister, 2005; Hutmacher and
Cool, 2007; Jones et al, 2007; Potier et al, 2007).
The requirement to include more of the above design
criteria into a single biomaterial construct has spurred
extensive investigation on the use of natural, synthetic,
and composite materials. Natural scaffolds such as
collagen type I, chitosan, calcium alginate, hyaluronic
acid and composites have been shown to be osteocon-
ductive, thus suitable for bone formation both in vitro and
in vivo (Solchaga et al, 2002; Abbah et al, 2006; Chang
et al, 2009; Chesnutt et al, 2009). However, a major
disadvantage is the lack of mechanical integrity. Alter-
natives with structural stability have been investigated,
including the use of synthentic polymers such as poly(lac-
tic acid) (PLA), poly(glycolic acid) PGA, co-polymer
polylactic-co-glycolic acid (PLGA), poly(methyl meth-
acrylate) (PMMA) and poly(caprolactone) (PCL). These
polymers exhibit the ability to support osteoblastic
differentiation and bone tissue formation, and are there-
fore commonly used for oral and maxillofacial applica-
tions (Li et al, 2005; Petrie et al, 2008; Kretlow et al,
2009). Additionally, polymer ⁄ ceramic composite materi-
als such as PLLA ⁄HA have been used successfully as
ostechondral constructs for TMJ engineering via the
delivery of porcine chondrocytes in the polymer layer and
fibroblasts transduced with adenovirus driving the
expression of bone morphogenetic proteins (BMPs)
(Schek et al, 2004, 2005).
Designing matrices suitable for the recruitment of
osteoprogenitor ⁄ stem cells has been promoted by the
approach of mimicking the composition, morphological
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traits and mechanical function of the native bone ECM
through the use of a wide range of electrospun bone
regenerative nanofiber materials such as PLLA, PGA,
PCL, silk fibroin, calcium phosphates, bioactive glass
and glass ceramics (Jang et al, 2009). The nanofibrous
structure is becoming increasingly useful and popular
within the field of craniofacial tissue engineering because
these materials are able to assist cells along an osteo-
genic pathway via nanoscale organization and novel
nanocomposite systems (Kim et al, 2006).
The addition of osteoinductive factors is also essential
to the success of craniofacial bone regeneration strate-
gies. BMPs, primarily 2, 4 and 7, fulfill this role in the
vast majority of applications. BMPs are a family of
growth factors important to bone formation and regen-
eration which have been studied extensively (Reddi,
2005) and are now available in a recombinant form for
human clinical application. One of the limiting factors in
this methodology has been the duration of the BMP’s
presence at the site of action with one of the potential
roles of the scaffolds being to assist in controlling
growth factor release. Importantly, the balance of
sustained release required for optimal effect while
avoiding overly high concentrations leading to potential
untoward effects must be managed.
Several preclinical models exist for the use of BMPs
and recombinant human BMP (rhBMP) as a concen-
trate delivered on scaffolds, composites, and hydrogels.
Defects studied have included animal models for ulna,
radius, femur, alveolar cleft, spine, orbital floor, tibia,
and calvarial defects (Bessa et al, 2008). At present, the
only FDA-approved craniofacial application of rhBMP
is for sinus augmentation. A recent report highlighting
this use enrolled 160 subjects in a multi-center, random-
ized prospective trial using rhBMP on a collagen sponge
versus autogenous bone graft for two-stage maxillary
sinus floor augmentation. Outcomes measured included
new bone formation, implant integration and functional
loading at 6 months and 2 years. Success rates for both
groups was 79% with significantly denser bone in the
rhBMP-2 group. In addition, the autograft group was
noted to have 17% long-term parasthesia, pain, or gait
disturbance, highlighting the effects of donor site
morbidity.
Limited clinical studies exist for tissue engineering
concepts other than BMPs and platelet-derived growth
factors (PDGF) in any body location. The majority of
evidence is derived from small case series without
controls and pertains to general orthopedic, rather than
craniofacial applications. In one study, three patients
with aneurysmal bone cyst, giant cell tumor, and fibrous
dysplasia were treated with implants based on HA
ceramics with multipotent stem cells induced toward the
osteoblast lineage. Successful healing was reported
although only based on plain radiographs and comput-
erized tomography. There were no adverse reactions
noted in this study with a limited number of patients
(Morishita et al, 2006).
The preclinical and clinical studies reviewed here
indicate that significant advancements are being made
in the design of biomaterials to create replacements
for damaged or pathological tissues. As biomaterials
become highly functionalized platforms upon which
hybrid tissues can develop, craniofacial tissue engineering
strategies hold significant promise for future clinical use.
Stem cell biology
From an embryological perspective, the structures of the
craniofacial region are predominantly derived from cells
of neural crest mesenchymal origin. These cells, together
with their synergistic partners, mesodermal cells, both
arise from the embryonic stem cell (Couly et al, 1993;
Jiang et al, 2002). Mesenchymal stem cells (MSCs) are
adult cells from this lineage that persist with the ability
to repair and regenerate tissue following insult. MSCs
have the genetic capacity to differentiate into both
mesenchymal and bone tissue lineage making them a
useful tool and target for research in tissue regeneration
(Krebsbach et al, 1997, 1999). Highlighting this poten-
tial is the fact that a single population of MSCs can
differentiate into both chondrocytes and osteoblasts
based on external factors to produce both bone and
cartilage. MSCs are self renewable lineages which were
first isolated and reported nearly four decades ago, and
since then, techniques for isolation have become
increasingly effective in regard to throughput and
specificity with current use of fluorescence-activated,
magnetic-activated cell-sorting, and genomic profiling
(Friedenstein et al, 1966; Gronthos et al, 1999; Jones
et al, 2002; Kinnaird et al, 2004). In addition, cloning
technology can be harnessed to create large quantities of
the desired cells. Given their properties, stem cells have
been utilized in a variety of preclinical applications for
regeneration of craniofacial bone.
One example of a complex bioengineering strategy for
craniofacial bone, highlighting its potential, is the
development of the mandibular condyle. It has been
shown that the generation of (i) a cadaveric human
mandibular condyle of bone and cartilage derived from
adult rat bone marrow MSCs, exposed to osteogenic
and chondrogenic conditions, and encapsulated in
poly(ethylene glycol) diacrylate (PEDGA) hydrogels
(Alhadlaq and Mao, 2003), and (ii) the vascularization
and ectopic tissue formation of an anatomically shaped
human tibia condyle made of a composite poly-
-caprolactone and hydroxyapatite material seeded with
osteogenically differentiated human MSCs after 6 weeks
of subcutaneous implantation in athymic rats (Lee et al,
2009), are possible. This suggests that optimal cell types
and local factors are required to make the possibility of
an engineered condyle look promising for human
application.
Adipose derived stem cells (ADSCs) are an alternative
progenitor cell source, in that these cells are easily
accessible through lipo aspirate and can be expanded
in vitro to form adipocytes, chondrocytes and osteo-
blasts (Zuk et al, 2001). Additionally, ADSCs have been
successfully applied to scaffolds and have undergone
de novo formation of bone in subcutaneous tissue,
calvarial defects, and critical sized bone defects in
murine models (Lee et al, 2003; Yoon et al, 2007; Hao
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et al, 2008). Translation of this technology to human
application has been reported with ADSCs combined
with iliac crest bone graft for a calvarial bone defect
(Zuk et al, 2001; Shi et al, 2005).
In addition to MSCs and ADSCs, there has been
extensive investigation into the capability of MSCs
derived from various craniofacial tissues that form
bone-like, dentin-like, and cementum-like structures.
For instance, dental pulp stem cells have been isolated
from dental pulp and in response to osteogenic condi-
tions, have been shown to express osteogenic and
odontogenic markers and form mineral deposits on
dentin-like structures (Gronthos et al, 2000; Murray
et al, 2001; Ueno et al, 2001). Periodontal ligament stem
cells (PDLSCs) first isolated, sorted, and cultured from
extracted third molars of human origin have been found
to differentiate into adipocytes and osteoblasts in vitro,
and generate cementum-like structures interfaced with
dense collagen fibers in vivo (Shi et al, 2002; Seo et al,
2004). Lastly, in vitro expansion of human exfoliated
deciduous teeth stem cells have been shown to have
proliferative capacity, a surface antigen profile similar to
MSCs, and have the ability to express osteogenic genes
and form dentin-like structures in vivo when seeded onto
HA ⁄TCP scaffolds (Miura et al, 2003).
Although the cell types discussed have potential for
great use for bone repair, given the complex nature of
craniofacial bone, the use of human embryonic stem
cells (hESCs) might provide a repository of cells that can
be isolated, manipulated, and utilized for future
cell-based engineering strategies (Thomson et al, 1998).
One goal for hESC research is the controlled differen-
tiation into specific progenitor cells for the purpose of
replacing or regenerating damaged tissue. Therefore, the
ability to obtain large quantities of multipotent cells
from hESCs represents a challenge for cell based
therapy and tissue engineering strategies that currently
rely on human bone marrow stromal cells (hBMSCs).
Recent studies show that mesenchymal precursors have
been derived from hESCs (hES-MSCs) via various
isolation methods, and the generation of osteoblasts
has been achieved in the presence of known osteogenic
supplements and co-culture with primary bone derived
cells (Sotille et al, 2003; Bielby et al, 2004; Barberi et al,
2005; Cao et al, 2005; Ahn et al, 2006, Karp et al, 2006;
Olivier et al, 2006; Duplomb et al, 2007; Karner et al,
2007; Tong et al, 2007; Arpornmaeklong et al, 2009;
Brown et al, 2009). However, the identification and
characterization of a pure osteoprogenitor cell popula-
tion has yet to be achieved. Osteoprogenitor cells
derived from hESCs have tremendous potential, as they
can serve as a tool through which one can not only
characterize early bone development and cellular behav-
ior on bone-related biomaterials but also have applica-
tion specifically in craniofacial bone repair.
To enhance the understanding of the differentiation
pattern and bone formation capacity of hESCs in the
skeletal defect, investigators have studied the complete
temporal pattern of osteoblastic differentiation of hES-
MSCs in a long-term culture, as well as the influence of
the three-dimensional matrix on the osteogenic differ-
entiation and bone formation capacity of hES-MSCs in
the calvarial defect. It was found that incubation of
hES-MSCs in osteogenic medium induced osteoblastic
differentiation in a similar chronological pattern to
previously reported human bone marrow stromal cells
(hBMSCs) and primary osteoblasts. Furthermore, it was
also demonstrated that differentiation was enhanced by
three-dimensional matrix of collagen scaffolds (Arporn-
maeklong et al, 2009). The fate of transplanted cells in
the bone formation process was verified by identifying
the presence of human cells in the matrix of the newly
formed bone, suggesting that hES-MSCs represent an
osteoprogenitor population that can be sorted, enriched
and manipulated for use in craniofacial engineering
strategies. Of particular importance is the fact that the
lineage progression through both mesodermal and
neural crest lineages can be controlled for hESCs,
addressing one of the major challenges unique to healing
the cranial skeletal given the dual embryonic origins
(Jiang et al, 2002; Mao et al, 2006; Lian et al, 2007;
Brown et al, 2009; Goldstein et al, 2010).
Gene therapy
Gene therapy depends on the transfer of genetic
material into living cells for the purposes of treating a
disease process or regenerating tissues. Both viral and
non-viral vectors for gene transfer have been developed
and applied to pre-clinical and limited clinical settings
(Scheller and Krebsbach, 2009). Non-viral vectors have
advantages attributable to safety and the ability to
introduce large segments of DNA; however, viral
vectors remain the mainstay of therapy as a result of
their efficacy in transmitting the genetic material to the
host. Compared with the focus of gene therapy on
treatment of disease, the use of gene therapy for the
regeneration of craniofacial bone has been somewhat
limited. However, animal craniofacial models for gene
therapy do exist not only for bone (Krebsbach et al,
2000; Dunn et al, 2005), but also for cartilage (Palmer
et al, 2002) and periodontal ligament (Jin et al, 2004) as
well as complex multiunit structures such as the TMJ
(Nakashima et al, 2006; Rabie et al, 2007) and salivary
glands (Cotrim et al, 2006; Voutetakis et al, 2008).
A number of applications are currently evolving with
promise for future augmentation of the bone healing
process or replacement of missing bone. BMPs have
maintained a prominent role in this model with potential
advantages of gene therapy conveying the ability to
maintain protein expression at clinically effective levels
over longer periods of time compared with direct
delivery of protein. In addition, because of the sustained
presence, gene delivery techniques are one of the few
modalities studied for potential application in irradiated
fields (Nussenbaum et al, 2003; Hu et al, 2010).
Enhanced fracture repair and bone formation have
been achieved using viral-mediated gene delivery. A
number of studies (Peng et al, 2004a; Shen et al,
2004a,b) using muscle-derived cells for ex vivo trans-
duction of bone resulted in fracture repair when placed
into femur critical sized defects. Transduction with
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BMP-4 leads to radiographic and histological healing
with bone, which was 77 ± 28% the strength of normal
control femur. Other work has demonstrated that the
addition of VEGF to BMP-4 enhances this process.
Likewise, other groups have reported a number of
studies using a similar approach with BMP-2 (Betz et al,
2010). In this model, an expedited ex vivo approach
where muscle or fat fragments were transduced with
BMP-2 and incubated in tissue culture only 24 h prior to
implantation. Moreover, the femoral critical size defect
model was used with radiographic and histological
evaluation. Bone volumes in the transduced sites showed
statistically significant increases in bone formation with
100% of bone defects being bridged in the study
animals. BMPs 6, 7 and 9 have also been utilized in
gene therapy bone repair models (Alden et al, 2000; Jane
et al, 2002) with similar abilities to induce bone forma-
tion.
While BMPs have been the most frequently investi-
gated factors for gene delivery, alternatives have been
described. Sonic hedgehog (Shh), PDGF-B, and consti-
tutively active activin-like kinase 2 (caALK2) have all
been investigated. Shh was studied in a craniofacial
model using rabbit cranial defects (Edwards 2005).
Human Shh cDNA was isolated from fetal lung tissue
and cloned into the replication-incompetent retroviral
expression vector LNCX. Alginate ⁄ type I collagen
constructs with Shh transduced cells were placed in
cranial defects and examined grossly, radiographically,
and histologically at 6 weeks. Shh treated animals had
statistically significant bone healing compared with
controls and no treatment related side effects were
noted. Interestingly, caALK2 has been investigated
using an allograft model for enhanced healing. Allo-
grafts were coated with AAV-caALK2 vector which
mediated in vivo gene transfer. The AAV vector was
capable of transducing osteoblasts in the fracture callus
and directly inducing bone formation (Anusaksathien
et al, 2004; Ulrich-Vinther, 2007).
In an effort to determine if regenerative gene therapy
methods could overcome the negative effects of radia-
tion therapy, animal models that more directly mimic
the compromised wound beds of irradiated cancer
patients have been used for testing ex vivo (Nussenbaum
et al, 2003) and in vivo (Hu et al, 2010) gene therapy. In
a critical size calvarial bone defect animal model, bone
defects were treated with an inlay calvarial bone graft or
transduced dermal fibroblasts. Two weeks postopera-
tively animals were randomized to receive 12-Gy radi-
ation or no radiation control. While radiation treatment
decreased the amount of bone formation from 87% to
65% bone regeneration was still successful giving
promise to the possibilities of treating ablative defects
prior to radiation therapy with these treatment modal-
ities (Nussenbaum et al, 2003).
An alternative approach to gain more control over the
timing of expression of transferred genes has been
the use of inducible vector systems. An example of this
is the doxycycline inducible tetON’ promoter system
with selective induction of BMP-2 or BMP-4. In bone
regeneration models, only vector containing sites
induced bone following administration of oral doxycy-
cline (Gafni et al, 2004; Peng et al, 2004b). Taken
together, these examples illustrate the potential benefits
of gene therapy over other bioengineering approaches
and will undoubtedly continue its progress as a leading
candidate for future clinical applications.
Conclusion
Craniofacial tissue engineering research has tremen-
dously developed over the last two decades as a result
of the individual strides made in the fields of develop-
mental biology, stem cell biology, polymer chemistry,
mechanical engineering, and biomedical engineering.
The unique challenges faced by maxillofacial surgeons
in the clinical setting has spurred investigation of
effective tissue engineering strategies that involve
isolated and enriched progenitor cells, sophisticated
gene delivery methods, and complex biomaterial
scaffold fabrication and design techniques. As we begin
to understand how biomaterial properties influence
cellular behavior, we will progress toward the develop-
ment of biomimetic scaffolds that contain incorporated
signaling cues that induce cellular differentiation and
ECM deposition, possess composite material properties
that have the ability to generate hybrid tissue, and have
tunable three-dimensional geometrical architecture that
appropriately restores form and function to craniofacial
bone defects.
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